Comparison of <scp>HiDAC</scp> Versus <scp>FLAG</scp>‐<scp>IDA</scp> in the Treatment of Relapsed Acute Myeloid Leukemia and High‐Risk Myelodysplastic Syndrome
While remission rates and survival outcomes were similar, FLAG-IDA was associated with longer periods of myelosuppression and transfusion dependency compared to HiDAC in these two cohorts. HiDAC can be considered as a salvage chemotherapyfor relapsed AML/HR-MDS based on our study.
Authors
- Arjan A. van de Loosdrecht (ORCID: https://orcid.org/0000-0001-8311-983X)
- Jeroen J. W. M. Janssen (ORCID: https://orcid.org/0000-0001-9567-1955)
- Jarom Heijmans (ORCID: https://orcid.org/0000-0001-9615-7851)
- Mesire Aydin (ORCID: https://orcid.org/0000-0002-4506-8186)
- Ellen Meijer (ORCID: https://orcid.org/0000-0002-4317-6554)
- Erfan Nur (ORCID: https://orcid.org/0000-0002-7069-930X)
- Man Tang (ORCID: https://orcid.org/0000-0001-9726-9943)
- David C. de Leeuw (ORCID: https://orcid.org/0000-0003-4591-8467)
- Mette D. Hazenberg (ORCID: https://orcid.org/0000-0002-5113-0249)
- Bart J. Biemond (ORCID: https://orcid.org/0000-0002-4426-5743)
- Deborah van der Tuin
- Marjolein L. Donker
- Sonja Zweegman (ORCID: https://orcid.org/0000-0002-5011-1820)
- Caroline E. Rutten
- Mariëlle J. Wondergem
Institutions
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Sanquin (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1111/ejh.14370
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45